期刊文献+

第Ⅴ结构域缺失型β_2-GPI对糖尿病大鼠尿蛋白排泄的影响 被引量:1

Effect of Domain Ⅴ Deletion of β_2-Glycoprotein Ⅰ on Urine Protein Excretion of Diabetic SD Rats
原文传递
导出
摘要 目的:探讨第Ⅴ结构域缺失型β2-糖蛋白I(DI-IV)对糖尿病大鼠24h尿蛋白排泄以及血管内皮生长因子(VEGF)-一氧化氮(NO)轴的影响。方法:将大鼠高脂喂养8周后尾静脉注射STZ(30mgkg-1)进行糖尿病造模,造模成功1周后将大鼠随机分为对照组、β2糖蛋白(Iβ2-GPI)组以及DI-IV组,每周分别于尾静脉注射人血清白蛋白(HSA)、β2-GPI、DI-IV各200mgkg-1,持续4周。于干预前后取血,测定血肌酐(Scr)、尿素氮(BUN)、血甘油三酯(TG)、总胆固醇酯(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、24h尿白蛋等。采用Westernblot检测肾脏VEGF、内皮源性一氧化氮合酶(eNOS)的表达及eNOS磷酸化。结果:与干预前相比,对照组、β2-GPI组TG、TC、LDL-C、HDL-C、Scr无明显变化(P均>0.05),而血糖、24h尿蛋白排泄升高(P均<0.05);干预后DI-IV组血TC、LDL-C、24h尿蛋白排泄均减少(P均<0.05)。与对照相比,DI-IV组肾脏VEGF-A表达减少(P<0.05),eNOS的磷酸化表达增加(P<0.05)。结论:DI-IV可能通过改善糖尿病大鼠肾脏VEGF-NO轴功能以及降脂作用,减轻糖尿病SD大鼠24h尿蛋白的排泄。 Objective: To investigate effect of domain V deletion of β2-glycoprotein I (DI-IV) on 24-hour urinary protein excretion ,VEGF-NO axis,and possible mechanisms in diabetic rats.Methods: Diabetic model was established with the use of SD rats, treated with intravenous injection of STZ (30mg/ kg) after a high fat diet for eight weeks. One week after successful modeling, the rats were randomly assigned to contro( group, 32 glycoprotein I (β2-GPI) group and DI-IV group, treated with intravenous injection of human serum albumin (HSA), β2-GPI or DI-IV with a dose of 200mg/kg every week ,for four weeks, respectively. Blood samples were taken before and after the intervention, and serum creatinine (Scr), blood urea nitrogen (BUN), serum triglyceride (TG), total cholesterol ester (TC), low- density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and 24-hour urinary protein were analyzed. Western blot was used to analyze the expression of VEGF and endothelial nitric oxide synthase (eNOS), and the phosphorylation of eNOS of rats' kidneys.Results: After intervention,TG,TC,HDL-C,Scr and LDL-C had no significant difference (p〉 0.05) while blood glucose and 24-hour urinary protein excretion increased (p 〈0.05) in control group and β2-GPI group;'lC,LDL-C, 24-hour urinary protein excretion decreased (p 〈0.05) in DI-IV group. VEGF-A expression in kidneys decreased more and phosphorylation of eNOS increased more in DI-IV group than in control group (p 〈0.05). Conclusion: DI-IV could relieve 24-hour urine protein excretion of diabetic SD rats. Possible mechanisms are to improve VEGF-NO axis function and lipid-lowering effect in diabetic rat kidneys.
出处 《临床药物治疗杂志》 2013年第2期14-17,36,共5页 Clinical Medication Journal
基金 国家自然科学基金项目(30971393 81070645) 天津市自然科学基金项目(10JCYBJC12000) 天津市卫生局科技基金重点项目及一般项目(09KZ01 09KZ89) 天津医科大学科技基金资助项目(2009ky25)
关键词 第Ⅴ结构域缺失型β2-糖蛋白I 糖尿病肾病 VEGF-NO轴 尿蛋白 domain V deletion of β2-glycoprotein I diabetic nephropathy VEGF-NO axis urinary protein
  • 相关文献

参考文献12

  • 1Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database [ J ]. Am J Kidney Dis, 2012, 59(1): 75-83.
  • 2Mironidou-Tzouveleki M, Tsartsalis S, Tomos C. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus [ J ] . Curr Drug Targets, 2011, 12(1): 107-114.
  • 3Nakagawa T, Sato W, Sautin YY, et al. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy [ J ]. J Am Soc Nephrol, 2006, 17(3): 736-745.
  • 4Advani A, Gilbert RE. The endothelium in diabetic nephropathy [ J ] . Semin Nephro, 2012, 32(2): 199-207.
  • 5Passam FH, Giannakopoulos B, Mirarabshahi P, et al. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2glycoprotein Ⅰ [ J ] . J Thromb Haemost, 2011, 9 (Suppl. 1): 275-282.
  • 6Yu P, Passam FH, Yu DM, et al. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor-induced angiogenesis through its amino terminal domain [ J ] . J Thromb Haemost, 2008, 6(7): 1215-1223.
  • 7Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein Ⅰ [ J ] . Curt Rheumatol Rep, 2011, 13(1): 90-95.
  • 8Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient [ J ] . Diab Vase Dis Res, 2008, 5(4): 319-335.
  • 9Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody [ J ] . Diabetes, 2002, 51(10):3090-3094.
  • 10Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothe|ial nitric oxide synthase knockout mice develop advanced diabetic nephropathy [ J ] . J Am Soc Nephrol, 2007, 18(2): 539-550.

同被引文献11

  • 1Nakagawa T,Sato W,Sautin YY,et al.Uncoupling of vascular endothelial growth factor with nitric xxide as a mechanism for diabetic vasculopathy.J Am Soc Nephrol,2006,17:736-745.
  • 2Faria AM,Papadimitriou A,Silva KC,et al.Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in ex perimental diabetes by re-establishing tetrahydrobiopterin levels.Diabetes,2012,61:1838-1847.
  • 3Kim M,Platt MJ,Shibasaki T,et al.G1P-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.Nat Med,2013,19:567-575.
  • 4Sturis J,Gotfredse CF,R(o)mer J,et al.GLP-1 derivative liraglutide in rats with β-cell deficiencies:influence of metabolic state on β-cell mass dynamics.Br J Pharmacol,2003,140:123-132.
  • 5Tian S,Gan Y,Li J,et al.Imbalance of glomerular VEGF-NO axis in diabetic rats:prevention by chronic therapy with propyl gallate.J Nephrol,2011,24:499-506.
  • 6Gaspari T,Welungoda I,Widdop RE,et al.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects onatherogenesis,plaque stability and endothelial function in an ApoE(-/-) mouse model.Diab Vasc Dis Res,2013,10:353-360.
  • 7Verspohl EJ.Novel therapeutics for type 2 diabetes:incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.Pharmacol Ther,2009,124:113-138.
  • 8Balakumar P,Chakkarwar VA,Krishan P,et al.Vascular endothelial dysfunction:a tug of war in diabetic nephropathy? Biomed Pharmacot her,2009,63:171-179.
  • 9Nakagawa T,Sato W,Glushakova O,et al.Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.J Am Soc Nephrol,2007,18:539-550.
  • 10杨文英.人GLP-1类似物利拉鲁肽的最新研究进展[J].中华内分泌代谢杂志,2010,26(9):840-843. 被引量:32

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部